Colorectal cancer (CRC) is one of the most prevalent and deadly cancers worldwide, affecting both men and women. Early detection through screening and diagnostics plays a critical role in reducing mortality rates, improving treatment outcomes, and enhancing overall survival rates. As the global awareness about colorectal cancer increases, so does the demand for advanced diagnostic tools and screening methods. This has spurred the growth of the colorectal cancer screening and diagnostics market, making it a critical segment in the healthcare industry.
Colorectal cancer originates in the colon or rectum and is typically associated with symptoms such as blood in the stool, weight loss, abdominal pain, and fatigue. However, many people with early-stage colorectal cancer experience no symptoms, which is why screening is vital for detecting the disease before symptoms appear. According to the World Health Organization (WHO), colorectal cancer is the third most common cancer worldwide, with over 1.9 million new cases and around 900,000 deaths annually. These statistics underline the importance of early detection and intervention.
The primary goal of colorectal cancer screening is to detect precancerous polyps or early-stage cancer in individuals who are at average or high risk. Early detection offers the best chance for effective treatment, which can significantly reduce the need for aggressive interventions like chemotherapy or surgery. There are several screening methods available, ranging from non-invasive tests to more complex procedures. These methods not only help in early detection but also in monitoring patients with a history of CRC or related conditions, improving the prognosis.